New Inhibitors for Parkinson's Disease Targeting LRRK2
Author Information
Author(s): Raig Nicolai D., Surridge Katherine J., Sanz-Murillo Marta, Dederer Verena, Krämer Andreas, Schwalm Martin P., Elson Lewis, Chatterjee Deep, Mathea Sebastian, Hanke Thomas, Leschziner Andres E., Reck-Peterson Samara L., Knapp Stefan
Primary Institution: Cold Spring Harbor Laboratory
Hypothesis
The study investigates the development of LRRK2-selective type-II kinase inhibitors for Parkinson's disease.
Conclusion
The new type-II inhibitors stabilize the inactive conformation of LRRK2, offering potential therapeutic options for Parkinson's disease.
Supporting Evidence
- The study presents the first LRRK2-selective type-II kinase inhibitors.
- These inhibitors are designed to target the inactive conformation of LRRK2.
- The inhibitors were developed using a combinatorial chemistry approach.
- Cellular assays and cryo-electron microscopy were used to analyze the inhibitors.
Takeaway
Scientists created new medicines that can help treat Parkinson's disease by targeting a specific protein in a different way than before.
Methodology
The inhibitors were designed using a combinatorial chemistry approach and tested through cellular assays and structural analysis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website